Teuber, A. http://orcid.org/0000-0002-5385-8735
Schulz, T. http://orcid.org/0000-0003-4070-7791
Fletcher, B. S.
Gontla, R. http://orcid.org/0000-0001-5918-7568
Mühlenberg, T. http://orcid.org/0000-0002-2078-8857
Zischinsky, M.-L.
Niggenaber, J. http://orcid.org/0000-0003-2942-263X
Weisner, J. http://orcid.org/0000-0002-6103-7371
Kleinbölting, S. B.
Lategahn, J. http://orcid.org/0000-0001-5993-7082
Sievers, S. http://orcid.org/0000-0003-0854-4507
Müller, M. P. http://orcid.org/0000-0002-1529-8933
Bauer, S. http://orcid.org/0000-0001-5949-8120
Rauh, D. http://orcid.org/0000-0002-1970-7642
Article History
Received: 11 July 2023
Accepted: 11 December 2023
First Online: 2 January 2024
Competing interests
: D.R. reports lecture and consulting fees from Pfizer, AZ, Sanofi, BI, and Bayer; is a shareholder of Centessa Pharmaceuticals plc., outside the submitted word. S.B. reports grants and personal fees from Blueprint Medicines, Incyte, and Novartis, PharmaMar, Eli Lilly & Co, Adcendo, Bayer, Blueprint Medicines, Boehringer Ingelheim, Cogent, Daiichi Sankyo, Deciphera, GSK, Exelixis, Novartis, Roche, PharmaMar. J.L. is a shareholder of Centessa Pharmaceuticals plc., outside the submitted work. The remaining authors declare no competing interests.